SLC39A1 could significantly decreased the level of Zn2 + in cancer tissue, thereby reducing the level of citrate, and ultimately resulting in the malignant progression of prostate cancer and glioma [30]. The gene discussed is SLC39A1; the disease is prostate carcinoma.